Innovative Research and Liaison Organization, Shinshu University, 3-1-1, Asahi, Matsumoto, Nagano, Japan.
Center for Advanced Research of Gene and Cell Therapy, Shinshu University, 3-1-1, Asahi, Matsumoto, Nagano, Japan.
Int J Clin Oncol. 2023 Jun;28(6):736-747. doi: 10.1007/s10147-023-02319-9. Epub 2023 Mar 2.
Since the introduction of the use of chimeric antigen receptor T-cell therapy (CAR-T therapy) dramatically changed the therapeutic strategy for B cell tumors, various CAR-T cell products have been developed and applied to myeloid and solid tumors. Although viral vectors have been widely used to produce genetically engineered T cells, advances in genetic engineering have led to the development of methods for producing non-viral, gene-modified CAR-T cells. Recent progress has revealed that non-viral CAR-T cells have a significant impact not only on the simplicity of the production process and the accessibility of non-viral vectors but also on the function of the cells themselves. In this review, we focus on piggyBac-transposon-based CAR-T cells among non-viral, gene-modified CAR-T cells and discuss their characteristics, preclinical development, and recent clinical applications.
嵌合抗原受体 T 细胞疗法（CAR-T 疗法）的应用引入极大地改变了 B 细胞肿瘤的治疗策略，各种 CAR-T 细胞产品已经被开发并应用于髓系和实体肿瘤。尽管病毒载体已被广泛用于产生基因工程 T 细胞，但基因工程的进步导致了非病毒、基因修饰的 CAR-T 细胞的产生方法的发展。最近的进展表明，非病毒 CAR-T 细胞不仅对生产过程的简单性和非病毒载体的可及性有重大影响，而且对细胞本身的功能也有重大影响。在这篇综述中，我们专注于非病毒、基因修饰的 CAR-T 细胞中的基于 piggyBac 转座子的 CAR-T 细胞，并讨论它们的特点、临床前开发和最近的临床应用。
